C2Sense
14 employees on LinkedIn · 2 known investors
Hyperion Biosystems builds diagnostic devices that use computer vision and physics-based algorithms to improve the sensitivity and specificity of point-of-care and at-home tests. Its products include the HALO platform and Helios, a rapid molecular diagnostic platform combining padlock probe chemistry, isothermal amplification, and optical readout for multiplexed, single-copy detection.
Also known as Hyperion Biosystems · Hyperion BioSystems
Investors · 2
Company profile
researched Aug 2026Hyperion Biosystems, operating at c2sense.com, designs diagnostic devices and software built on computer vision and physics-based algorithms, positioning its technology as a way to raise assay performance at low cost. Its HALO platform is aimed at identifying false positives, delineating non-specific binding and mitigating assay defects, so that customers can improve assay performance without redesigning their existing tests.
The company also announced Helios, a rapid molecular diagnostic platform that combines padlock probe chemistry with isothermal amplification and an optical readout. Helios is described as capable of detecting hundreds to thousands of targets simultaneously at single-copy sensitivity levels in under three hours using standard laboratory equipment. In addition to diagnostics, the company jointly developed an anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products, licensed to Colorcon for commercialization.
Business model
The company works with established point-of-care and at-home testing companies, supplying algorithmic and platform technology that enhances their diagnostic products without requiring those partners to divert or disrupt internal resources. It has also licensed jointly developed technology to a commercial partner for market commercialization.
Traction
The company reports an average sensitivity enhancement of 10x, 10,000 assays run with its algorithms, and 14 examples of custom solutions delivered in a week or less. It has secured two NIH RADx awards together with Princeton BioMeditech and entered a licensing agreement with Colorcon.
Latest developments
In January 2026 the company introduced Helios, its rapid molecular diagnostic platform. In May 2025 it announced a licensing agreement with Colorcon covering a jointly developed anti-counterfeiting technology. In May 2024 Dr. Michael Mina, MD, PhD, joined the board of directors as an independent director, and in April 2024 the company and Princeton BioMeditech received a second NIH RADx award.
▸Full profile — market position, technology, go-to-market
Market position
The company frames its approach as improving sensitivity and specificity of existing diagnostic offerings through algorithms rather than assay redesign, and its Helios platform as delivering highly multiplexed, single-copy-sensitivity detection on standard laboratory equipment.
Technology
HALO applies computer vision and physics-based algorithms to assay readouts to identify false positives, delineate non-specific binding and mitigate assay defects. Helios is a rapid molecular diagnostic platform combining padlock probe chemistry, isothermal amplification and an optical readout to detect hundreds to thousands of targets simultaneously at single-copy sensitivity in less than three hours on standard laboratory equipment.
Go-to-market
Partnership-led: the company collaborates with diagnostics manufacturers and testing market incumbents, licenses jointly developed technology to commercial partners such as Colorcon, and participates in federally funded programs such as the NIH RADx initiative alongside Princeton BioMeditech.
Leaders in the point-of-care and at-home diagnostic testing markets, and, for its anti-counterfeiting technology, makers of solid oral dosage pharmaceutical and nutraceutical products.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2014 | $145.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Timeline · 4
launches, deals, and filingsHelios combines padlock probe chemistry, isothermal amplification and an optical readout to simultaneously detect hundreds to thousands of targets at single-copy sensitivity levels in less than three hours using standard laboratory equipment.
Hyperion Biosystems and Colorcon announced a licensing agreement to commercialize and market a jointly developed anti-counterfeiting technology for solid oral dosage pharmaceutical and nutraceutical products.
Dr. Michael Mina, MD, PhD, joined the Hyperion Biosystems Board of Directors as an independent director, effective May 24, 2024; announced May 28, 2024.
Hyperion Biosystems and Princeton BioMeditech announced they secured a second NIH RADx award.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 1
primary sources listed
- C2Sensec2sense.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does C2Sense do?
- Hyperion Biosystems develops computer-vision and algorithm-based technology to improve point-of-care and at-home diagnostic tests.
- Who are C2Sense's investors?
- C2Sense's investors include Newlin Investment Company LLC, Safar Partners.